Skip to main content Help with accessibility Skip to main navigation

Bimekizumab

Indication

Axial spondyloarthritis (NICE TA918)

NICE TA918 - Bimekizumab for treating axial spondyloarthritis

Red

Brand:

Nice TA:

918

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Musculoskeletal system

Background

1.1 Bimekizumab is recommended as an option in adults for treating active ankylosing spondylitis (AS) when conventional therapy has not worked well enough or is not tolerated, or active non‑radiographic axial spondyloarthritis (nr‑axSpA) with objective signs of inflammation (shown by elevated C‑reactive protein or MRI) when non-steroidal anti‑inflammatory drugs (NSAIDs), have not worked well enough or are not tolerated. It is recommended only if:

  • tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and

  • the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 11 - Jan - 2024